Recombinant antibody production utilizing Chinese Hamster Ovary (CHO) cells offers a critical platform for the development of therapeutic monoclonal antibodies. Enhancing this process is essential to achieve high yields and quality antibodies. A variety of strategies can be employed to optimize ant